ArticleStem cell research & therapy2025
Chemical direct conversion of human fibroblasts to mesenchymal stem cells that can alleviate inflammation in vivo.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances and Challenges in 3D Bioprinting of Cartilage Organoids: From Material Innovation to Functional Regeneration.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMesenchymal stem cell (MSC) transplantation may significantly benefit patients with some inflammatory diseases. However, invasive procedures are required to collect autologous MSCs from patients, while in vitro expansion of MSCs may spoil their stemness. In this study, we aimed to induce MSC-like phenotypes in human dermal fibroblasts (HDFs).
methodsHDFs were cultured with some chemical compounds. The resultant cells were examined for their gene expression and multi-differentiation abilities in vitro. Anti-inflammatory functions in vivo were tested using two types of disease models in mice. Exosomes derived from the cells were also characterized.
resultsA combination of a TGF-β receptor inhibitor, a ROCK inhibitor, and an ATM inhibitor provoked HDFs to strongly express MSC markers. The chemical compound-driven directly converted MSCs (cdMSCs) had multilineage differentiation potentials to osteogenic, chondrogenic, and adipogenic lineages in vitro. The genes related to TGF-β, MAPK, Hedgehog and WNT signaling pathways were remarkably changed in expression levels, while CpG DNA methylation statuses were also altered, during the cell type transition. The cdMSCs ameliorated both acute and chronic inflammatory diseases after transplantation into murine models of LPS-induced lung injury and autoimmune arthritis. The cdMSCs secreted exosomes that promoted polarization of M0 macrophages to M2 phenotype while suppressing M1 macrophage induction in vitro.
conclusionThe three compounds successfully converted HDFs into MSC-like cells with high anti-inflammatory activities, which would be useful in regenerative medicine for inflammatory disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.